Literature DB >> 16870288

Manually after-loaded 192Ir low-dose rate brachytherapy after subtotal excision and flap reconstruction of recurrent cervical lymphadenopathy from head and neck cancer.

Christopher Nutting1, Nigel Horlock, Roger A'Hern, Adam Searle, J Michael Henk, Peter Rhys-Evans, Kevin Harrington.   

Abstract

BACKGROUND: Treatment of extensive recurrent cervical lymph node metastases from previously irradiated head and neck cancer represents a difficult clinical challenge. We report the results of an approach of maximal surgical debulking and manually after-loaded intra-operative brachytherapy. PATIENTS AND METHODS: Seventy-four procedures were carried out at the Royal Marsden Hospital between 1979 and 2003. All patients had previously been treated with radical radiotherapy or chemoradiation. Patients underwent maximal surgical debulking, followed by brachytherapy to the tumour bed with low-dose rate (192)Ir to a dose of 60 Gy to the reference isodose using the Paris system.
RESULTS: Overall and disease specific survival rates were 31% and 28% at two years and 23% and 17% at five years. Corresponding Loco-regional control rates were 37% and 23%, respectively. Fifty per cent of patients developed metastatic disease within 5 years of treatment. Best results were obtained with surgical excision, brachytherapy and reconstruction of the skin defect using a vascularised myo-cutaneous flap with in-field control rates of 72% at two years and 66% at 5 years. Nine per cent of patients developed fistulae, 4% had haemorrhage and 8% wound breakdown/infection.
CONCLUSIONS: Maximal surgical debulking, including removal of overlying skin, and brachytherapy to the surgical tumour bed provides high levels of local control, and can be achieved with acceptable morbidity. Only a minority of patients achieve long-term survival because of the high risk of systemic relapse.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870288     DOI: 10.1016/j.radonc.2006.06.012

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Intensity modulated perioperative HDR brachytherapy for recurrent and/or advanced head and neck metastases.

Authors:  Ingo U Teudt; György Kovàcs; Matthias Ritter; Corinna Melchert; Tamer Soror; Barbara Wollenberg; Jens E Meyer
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-23       Impact factor: 2.503

2.  [Brachytherapy for the treatment of head and neck cancer].

Authors:  J E Meyer; C Brocks; S Maune; V Strnad; J A Werner; B Wollenberg; G Kovács
Journal:  HNO       Date:  2010-09       Impact factor: 1.284

Review 3.  Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy.

Authors:  György Kovács
Journal:  J Contemp Brachytherapy       Date:  2014-12-31

4.  The role of salvage surgery with interstitial brachytherapy for the Management of Regionally Recurrent Head and Neck Cancers.

Authors:  Nayel Khan; Mark Clemens; Jun Liu; Adam S Garden; Anne Lawyer; Randal Weber; G Brandon Gunn; William H Morrison; Michael E Kupferman
Journal:  Cancers Head Neck       Date:  2019-07-22

Review 5.  A systematic review of treating recurrent head and neck cancer: a reintroduction of brachytherapy with or without surgery.

Authors:  Julianna Rodin; Voichita Bar-Ad; David Cognetti; Joseph Curry; Jennifer Johnson; Chad Zender; Laura Doyle; David Kutler; Benjamin Leiby; William Keane; Adam Luginbuhl
Journal:  J Contemp Brachytherapy       Date:  2018-10-31

6.  Single institution implementation of permanent 131Cs interstitial brachytherapy for previously irradiated patients with resectable recurrent head and neck carcinoma.

Authors:  Voichita Bar-Ad; Emily Hubley; Adam Luginbuhl; David Cognetti; Joseph Curry; Amy S Harrison; Jennifer M Johnson; James Keller; Cheng Peng; David To; Laura Doyle
Journal:  J Contemp Brachytherapy       Date:  2019-06-28

7.  Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.

Authors:  M Ritter; I U Teudt; J E Meyer; U Schröder; G Kovács; B Wollenberg
Journal:  Radiat Oncol       Date:  2016-01-20       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.